TLDR
- IBRX stock jumps 4.32% after FDA accepts ANKTIVA sBLA review for NMIBC.
- ANKTIVA plus BCG could treat papillary-only NMIBC, expanding patient options.
- QUILT 3.032 trial shows 12-month DFS of 58.2% in papillary NMIBC patients.
- Progression-free survival at 36 months remains 82%, supporting bladder preservation.
- FDA sBLA review highlights biological overlap between CIS and papillary disease.
ImmunityBio (IBRX) shares jumped to $8.10, rising 4.32%, after the FDA accepted the supplemental BLA for ANKTIVA. The filing seeks to expand ANKTIVA plus BCG use in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors. This regulatory step marks a significant potential treatment expansion for patients with limited options.
FDA sBLA Review and Clinical Focus
The FDA set a PDUFA action date of January 6, 2027, for the ANKTIVA sBLA review. The agency emphasized evaluating scientific data on papillary NMIBC and its overlap with carcinoma in situ (CIS). Cohort B data from the QUILT-3.032 trial, along with prior Cohort A results, underpin the expansion rationale for the ANKTIVA indication.
The sBLA review will focus on disease biology and clinical trial efficacy evidence. The FDA highlighted single-arm trial limitations in papillary-only cases while noting parallels with prior approvals. These evaluations aim to confirm if ANKTIVA plus BCG can safely and effectively treat papillary-only NMIBC.
The public FDA workshop on May 18, 2026, addressed NMIBC trial design and interpretation. Experts discussed biological similarities between CIS and papillary disease. The workshop affirmed current real-world treatment patterns, which align with expanding ANKTIVA access for papillary-only patients.
QUILT 3.032 Trial and Treatment Outcomes
The QUILT 3.032 Phase 2/3 trial enrolled 80 patients with high-grade papillary-only NMIBC. The study reported a 12-month disease-free survival (DFS) rate of 58.2%, meeting its primary endpoint. Secondary endpoints tracked progression-free survival, cystectomy-free survival, and disease-specific survival.
Progression-free survival reached 94.9% at 12 months and 82% at 36 months. Cystectomy-free survival remained above 92% at 12 months and 83.1% at 36 months. Disease-specific survival was 96% at 36 months, highlighting durable benefits for bladder preservation.
Safety outcomes mirrored the existing ANKTIVA indication. Serious adverse events were consistent with BCG monotherapy, confirming tolerability in papillary-only patients. These findings support potential broader adoption of ANKTIVA plus BCG.
Market and Clinical Implications
ANKTIVA plus BCG received prior FDA approval in April 2024 for CIS with or without papillary tumors. Papillary disease represents approximately 85% of NMIBC cases in the U.S., showing substantial patient impact. Expanding the ANKTIVA indication could improve bladder-sparing options for a larger patient population.
Category 2A NCCN guidelines now recognize papillary-only disease treatment with ANKTIVA plus BCG. Clinicians currently manage papillary patients using approved therapies for CIS and papillary NMIBC. FDA acceptance of the sBLA may enhance insurance reimbursement and treatment availability.
This regulatory milestone underlines ImmunityBio’s commitment to immunotherapy innovation. The stock surge reflects market recognition of the sBLA’s potential impact on NMIBC care. If approved, ANKTIVA plus BCG could reshape treatment pathways for high-grade papillary NMIBC.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
